David Morrison | Eli Lilly via AP
Eli Lilly’s late-stage trial of its major monoclonal antibody treatment for coronovirus has been halted by US health regulators over potential safety concerns, the company confirmed to CNBC on Tuesday.
Mola McCull, a spokesperson, told CNBC, “Security is of utmost importance to Lily. We know that, with an abundance of caution, the ACTIV-3 Independent Data Security Monitoring Board (DSMB) has recommended a nomination stagnation. ” “Lily is a supporter of the decision by the Independent (Data Security Monitoring Board) to carefully ensure the safety of patients participating in this study.”
Shares of the company fell nearly 3% in afternoon trading after news leaked on Twitter.
The test of ACTIV-3 is designed to test a monoclonal antibody developed by Eli Lilly with Remedisvir, which is viral with the Emergency Use Authority for the virus. It is one of several ongoing trials that are part of the “Activity” program of the National Institutes of Health, designed to accelerate the development of Kovid-19 vaccines and therapies. This operation is also supported by the Tana momentum, producers of the Trump administration and the effort to distribute vaccines to fight Kovid-19.
Eli Lilly’s drug is part of a class of treatments known as monoclonal antibodies, designed to act as immune cells, which scientists hope can fight the virus. This treatment was developed using the blood sample of one of the first American patients who recovered from Kovid-19. AstraZeneca and Regeneron, among other companies, are also working on so-called antibody treatments.
Monoclonal antibody treatment broke headlines this month after reports that President Donald Trump received an antibody cocktail from Regenerative Pharmaceuticals. As Trump’s health improved, he changed it to “cure”. But Regeron CEO Leonard Sleifer has insisted that more testing is needed.
There is no information yet about Eli Lilly’s security concerns.
“When scientists test promising treatments, sometimes unexpected side effects occur,” said Jeremy Faust, health policy expert and emergency medicine physician at Brigham and Women’s Health.
Faust was part of a group of scientists who first reported this news through research site Brief 19.
“When only a small number of patients have received a compound, it is difficult to tell what the real problem is and the noise,” he told CNBC. “This is why patience and discretion are always warranted before experimental treatments fail.”